Browse our Medical Journals

Among all scientific traditions alive, medical publishing has a good chance to be the oldest. The first fully peer reviewed academic journal, “Medical Essays and Observations” was launched in 1731 by the Royal Society in Edinburgh. Since then, hundreds of medical journals have been published worldwide. Medical publication in Hungary started in 1857 when the famous physician, Markusovszky founded “Orvosi Hetilap”, which has been published since then every week (with short breaks during the world wars). It is now a most prestigious piece in AKJournals’ portfolio, listed in Journal Citation Reports, with a remarkable impact factor.

Discover the latest journals in Medical and Health Sciences

The primary function of medical articles is the validation of cutting-edge theoretical and clinical research, by providing reference and relevant forums. New drugs and medical practices can only enter the mainstream practise if their randomised trials had passed under the critical lens of prestigious peer reviewed journals. Technical reports help practitioners to improve their arsenal. Case reports confirm theories and provide tools for investigating or disclosing possible malpractice. Review articles serve educational purposes. Some more popular articles may play a role in educating the interested audience.

Types of medical articles

The papers published in medical journals can be classified in the following main categories

  • Research articles report about novel research results, of both theoretical and (direct or indirect) practical relevance.
  • Review articles survey specific topics by summarising and analysing all information available in the medical literature. Reviews are kind of combining results from different studies on the same topic. They can be useful for specialists in the field, may help them to prevent, diagnose, or treat a particular disease.
  • Case reports and case series reports about a concrete story of a concrete patient. They can be interesting because of their uniqueness, not matching any known diagnosis or describing unexpected symptoms. The report should describe each of the diagnosis, treatment, the patient’s response to it and the follow-up history. Case series are related reports about similarly treated patients.
  • Editorials are typically not peer reviewed shorter communications from senior members of the Editorial Board or from invited renown scholars. They discuss questions of relevance for the scientific community at the moment (say, about public health, or more generally, the health system).
  • Letters to the editor are articles of the interactive type, a form for readers to contact the medical journal. They can express comments, questions, or criticisms regarding some articles published in that journal. They provide a sophisticated forum for medical communities.

Medical Journals at AKJournals

AKJournals has 9 medical journals. Three of them are in Hungarian. The other six journals are in English and accept submissions from all over the world. Some of them are widely available Open Access journals. The covered topics include immunology, medical imaging, physiology, and veterinary and health care science. In these journals, you can find more than 11.000 medical articles altogether. A filter tool helps to single out the relevant titles. In addition to that, we highly recommend using the search box to find the most important topics only

Medical and Health Sciences

You are looking at 1 - 10 of 11,162 items for

  • All content x
Clear All

Abstract

Based on the current literature, the link between Achilles tendon moment arm length and running economy is not well understood. Therefore, the aim of this study was to further investigate the connection between Achilles tendon moment arm and running economy and the influence of Achilles tendon moment arm on the function of the plantarflexor muscle-tendon unit during running.

Ten male competitive marathon runners volunteered for this study. The participants ran on a treadmill at two running speeds: 3 and 3.5 m s−1. During running the oxygen consumption, lower leg kinematics, electrical activity of plantar flexor muscles, and fascicle behavior of the lateral gastrocnemius were measured simultaneously. On the second occasion, an MRI scan of the right leg was taken and used to estimate the Achilles tendon moment arm length.

There was a negative correlation between running economy and the body height normalized moment arm length at both selected speeds (r = −0.68, P = 0.014 and r = −0.70, P = 0.01). In addition, Achilles tendon moment arm length correlated with the amplitude of the ankle flexion at both speeds (r = −0.59, P = 0.03 and r = −0.60, P = 0.03) and with the electrical activity of the medial gastrocnemius muscle at 3 m s−1 speed (r = −0.62, P = 0.02). Our finding supports the concept that a longer moment arm could be beneficial for distance runners.

Open access

Abstract

In this study, the ability of microRNA-1906 (miR-1906) to attenuate bone loss in osteoporosis was evaluated by measuring the effects of a miR-1906 mimic and inhibitor on the cellular toxicity and cell viability of MC3T3‐E1 cells. Bone marrow-derived macrophage (BMM) cells were isolated from female mice, and tartrate-resistant acid phosphatase signalling was performed in miR-1906 mimic-treated, receptor-activated nuclear factor kappa-B (NF-κB) ligand (RANKL)-induced osteoclasts. In-vivo, osteoporosis was induced by ovariectomy (OVX). Rats were treated with 500 nmol/kg of the miR-1906 mimic via intrathecal administration for 10 consecutive days following surgery. The effect of the miR-1906 mimic on bone mineral density (BMD) in OVX rats was observed in the whole body, lumbar vertebrae and femur. Levels of biochemical parameters and cytokines in the serum of miR-1906 mimic-treated OVX rats were analysed. The mRNA expression of toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), p-38 and NF-κB in tibias of osteoporotic rats (induced by ovariectomy) was observed using quantitative reverse-transcription polymerase chain reaction. Treatment with the miR-1906 mimic reduced cellular toxicity and enhanced the cell viability of MC3T3‐E1 cells. Furthermore, osteoclastogenesis in miR-1906 mimic-treated, RANKL-induced osteoclast cells was reduced, whereas the BMD in the miR-1906 mimic-treated group was higher than in the OVX group of rats. Treatment with the miR-1906 mimic also increased levels of biochemical parameters and cytokines in the serum of ovariectomised rats. Finally, mRNA expression levels of TLR4, MyD88, p-38 and NF-κB were lower in the tibias of miR-1906 mimic-treated rats than in those of OVX rats. In conclusion, the miR-1906 mimic reduces bone loss in rats with ovariectomy-induced osteoporosis by regulating the TLR4/MyD88/NF‐κB pathway.

Restricted access
Acta Veterinaria Hungarica
Authors: Violetta M. Yurakhno, Vladimir N. Voronin, Sergey G. Sokolov, Julia M. Malysh, Alexandr P. Kalmykov, and Yuri S. Tokarev

Abstract

Loma acerinae is a xenoma-forming fish microsporidium described from common ruffe Gymnocephalus cernua (Perciformes: Percidae) and also found in Ponto-Caspian gobies (Gobiiformes: Gobiidae). This casts doubt on the strict host specificity of this parasite. The largest subunit RNA polymerase II (rpb1) was used as a genetic marker of the parasite isolated from six host species of Perciformes (G. cernua from the Baltic Sea), Atheriniformes (Atherina boyeri from the Azov Sea) and Gobiiformes (Neogobius spp. and Zosterisessor ophiocephalus from the Black Sea and Ponticola kessleri from the Caspian Sea basin). Two major rpb1 haplogroups were found with 98.5% identity between the groups. Notably, Haplogroup I was associated with Neogobius spp. samples (n = 6) only, whereas Haplogroup II included the samples from other host species (n = 7). These findings confirm the broad distribution and host range of L. acerinae, but also indicate that certain patterns of host-driven intraspecific polymorphism may exist. Furthermore, the study revealed low similarity between the ribosomal RNA gene sequences of L. acerinae and the type species, Loma morhua (as well as other species of the genus). This suggests loose genetic association within the genus, and may raise the need for the taxonomic revision of L. acerinae.

Restricted access

Abstract

Interferon-induced transmembrane protein 3 (IFITM3) plays a pivotal role in antiviral capacity in several species. However, to date, investigations of the IFITM3 protein in cattle have been rare. According to recent studies, interspecific differences in the IFITM3 protein result in several unique features of the IFITM3 protein relative to primates and birds. Thus, in the present study, we investigated the bovine IFITM3 protein based on nucleotide and amino acid sequences to find its distinct features. We found that the bovine IFITM3 gene showed a significantly different length and homology relative to other species, including primates, rodents and birds. Phylogenetic analyses indicated that the bovine IFITM3 gene and IFITM3 protein showed closer evolutionary distance with primates than with rodents. However, cattle showed an independent clade among primates, rodents and birds. Multiple sequence alignment of the IFITM3 protein indicated that the bovine IFITM3 protein contains 36 bovine-specific amino acids. Notably, the bovine IFITM3 protein was predicted to prefer inside-to-outside topology of intramembrane domain 1 (IMD1) and inside-to-outside topology of transmembrane domain 2 by TMpred and three membrane embedding domains according to the SOSUI system.

Restricted access

Összefoglaló. Az akut promyelocytás leukémia (APL) ritka, de jól gyógyítható leukémiatípus. Az APL-es betegek gondozását centralizáltan, az APL kezelésében jártas kórházakban kell végezni, ahol elérhető hematológiai intenzív ellátás. Az APL terápiája az elmúlt két évtizedben rohamosan fejlődött az igen aktív hatású gyógyszerek, a tretinoin és az arzén-trioxid bevezetésével. Immáron a hagyományos citotoxikus kemoterápia alkalmazása nélkül kezelhető a betegség. A legújabb klinikai irányelvek többféle kezelési stratégiát tartalmaznak, ezek egy része továbbra is alkalmazza a citotoxikus kemoterápiát. Ily módon számos kezelési lehetőség áll a gyakorló hematológus rendelkezésére, amikor egy új APL-es beteg ellátását tervezi. Az elmúlt három évtized multicentrikus vizsgálatai igazolták az ATRA + kemoterápia, majd később a kemoterápiával vagy anélkül adott ATRA + ATO alkalmazásának hatásosságát. Az APL optimális kezeléséhez azonban a diagnózis korai felállítása, az agresszív szupportív beavatkozások bevezetése, a kezeléssel összefüggő szövődmények megfelelő rendezése és a mérhető reziduális betegség (az MRD) monitorozása is hozzátartozik. A szerzők az akut promyelocytás leukémia legújabb kezelési irányelveit foglalják össze.

Summary. Acute promyelocytic leukemia (APL) is an uncommon but highly curable leukemia. Treatment of APL patients should be centralised in hospitals with proven experience in APL treatment and haematological intensive care. The treatment of acute promyelocytic leukemia (APL) has evolved rapidly in the past two decades after the introduction of highly active drugs, including tretinoin (all-trans-retinoic acid) and arsenic trioxide. It is now possible to treat this disease without the use of traditional cytotoxic chemotherapy. Today’s clinical guidelines include multiple regimens, some of which continue to use cytotoxic chemotherapy. This leaves the practicing oncologist with multiple treatment options when faced with a new case of APL. Multicenter studies over the past three decades have demonstrated the efficacy of ATRA plus chemotherapy and, subsequently, of ATRA plus ATO, with or without chemotherapy. However, the optimal management of APL also requires early diagnosis, institution of aggressive supportive measures, appropriate management of treatment-related complications and monitoring of measurable residual disease (MRD). The authors summarizes the updated guidelines in the management of acute promyelocytic leukemia.

Open access
Restricted access

Összefoglaló. A mély molekuláris remisszióban lévő CML-es betegnél láz, izomfájdalmak alakultak ki, melyet jelentős kétvonalas cytopenia kísért. Alapbetegségének blasztos transzfomációja mellett, az utazási anamnézisre tekintettel a differenciáldiagnosztika trópusi betegségekre is kiterjedt. Dengue-lázat diagnosztizáltunk, melyből a beteg szövődmény nélkül felépült.

Summary. A CML patient in deep molecular remission was admitted with fever, muscle pain, followed by pronounced bilineage cytopenia. In addition to possible blastic transformation, tropical diseases were also included in the differential diagnosis, due to travel history. Dengue fever was diagnosed, and the patient recovered without any complications.

Restricted access
Hematológia–Transzfuziológia
Authors: Apor Hardi, András Kozma, Andrea Ceglédi, Ágnes Tomán, András Bors, Hajnalka Andrikovics, and Gábor Mikala

Összefoglaló. A monoklonális ellenanyagokat termelő plazmasejtburjánzás, a myeloma multiplex kezelésére a monoklonális ellenanyag-terápia viszonylag későn lépett a klinikumba. 2020 végén már három törzskönyvezett antitest, az elotuzumab, a daratumumab és az isatuximab áll rendelkezésre különböző gyógyszer-kombinációk részeként a myeloma betegség eltérő terápiás helyzeteinek megoldására. Emellett számos új antitest, nemcsak „csupasz” antitestek, hanem antitestdrug konjugátumok és bispecifikus antitestek állnak viszonylag előrehaladott klinikai fejlesztési stádiumban, közvetlenül a bevezetés előtt. Összefoglalónkban a rendelkezésünkre álló nagyszámú tanulmány eredményeit ismertetjük, fogódzót kínálva a terület eredményeit kritikus szemmel megismerni kívánó olvasóknak.

Summary. Although multiple myeloma is a plasma cell malignancy known to produce monoclonal antibodies, therapeutic monoclonal antibodies entered late into this clinical field. At the end of 2020, we already have three approved monoclonal antibodies: elotuzumab, daratumamab, and isatuximab – available in different drug combinations at different therapeutic settings of multiple myeloma. Additionally, there are a number of new antibodies, not just „bare” antibodies but antibody-dug conjugates and bispecific antibodies stand at advanced stages of clinical development, frequently just before approval. In this review, results of the large number of clinical studies are critically detailed in order to provide assistance for our interested readers.

Restricted access